Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid Tumors
Mingyu Huo, Dan Li, Nan Li, Alex Quan, Tianyuzhou Liang, Dan Henderson, Jason G. Sagert, Minh Pharm, Luke Hanley, Kelly Maeng, Mikhala Eule, Mitchell Ho
This study develops allogeneic CRISPR-engineered CAR-T cells targeting GPC2 and GPC3, showing potent antitumor activity in solid tumors with repeated dosing and no toxicity.
bioRxiv · Apr 29, 2026 · PreprintImmunology